Genomic profiling for defining luminal subtypes | Dr Harold Burstein at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, explains the development of multigene tests, such as the Oncotype DX® Breast Cancer Assay and the PAM50 test, for classifying breast cancer into different subtypes. Luminal A and B subtypes of breast cancer may have important predictive value in the clinic.

This content is supported by Genomic Health, Inc.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews